Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY ) stock plunged on Thursday after the company lowered its fiscal 2026 guidance. The company reported second-quarter adjusted earnings of $1.84 per share, beating the consensus of $1.55. Sales jumped 67% year over year to $1.291 billion, missing the consensus of $1.323 billion.